Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 10/2010

01.10.2010 | Retinal Disorders

Multimodal fundus imaging in Best vitelliform macular dystrophy

verfasst von: Daniela C. Ferrara, Rogério A. Costa, Stephen Tsang, Daniela Calucci, Rodrigo Jorge, K. Bailey Freund

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Best vitelliform macular dystrophy (BVMD) is a rare autosomal dominant retinal disease of highly variable phenotypic expression. Interpretations of disease mechanisms based on histopathology, electrophysiology, genetic analysis, and retinal imaging are somewhat discordant in fundamental issues such as the location and extension of primary retinal changes. Herein we describe the morphological macular features in patients with BVMD undergoing simultaneous multimodal fundus imaging and compare to those of normal age-matched subjects.

Methods

Comparative study including seven patients with BVMD (14 eyes) and seven age-matched healthy subjects (14 eyes). All participants were submitted to complete ophthalmological examination, fundus photography, and standardized multimodal fundus imaging protocol including Fourier-domain optical coherence tomography (Fd-OCT) combined with near-infrared reflectance and blue-light fundus autofluorescence (FAF).

Results

In two eyes in the “subclinical” stage, Fd-OCT revealed thickening of the middle highly reflective layer (HRL) localized between the photoreceptors’ inner/outer segments junction (inner-HRL) and RPE/Bruch’s membrane reflective complex (outer-HRL) throughout the macula. In one eye in the “vitelliform” stage, a homogeneous hyper-reflective material on Fd-OCT was observed between the middle-HRL and outer-HRL; this material presented increased fluorescence on FAF. The outer nuclear layer (ONL) was thinned in the central macula and subretinal fluid was not identified in these earlier disease stages. In patients of “pseudohypopyon” (two eyes), “vitelliruptive” (eight eyes) and “atrophic” (one eye) stages, Fd-OCT revealed a variety of changes in the middle- and inner-HRLs and thinning of ONL. These changes were found to be associated with the level of visual acuity observed. Thickening of the middle-HRL was observed beyond the limits of the clinically evident macular lesion in all eyes.

Conclusions

Multimodal fundus imaging demonstrated thickening of the reflective layer corresponding to the photoreceptors’ outer segments throughout the macula with no subretinal fluid accumulation as the earliest detectable feature in BVMD. Changes detected in the photoreceptors’ reflective layers (middle- and inner- HRLs) and ONL thinning seemed to be progressive with direct implications for the level of visual acuity impairment observed among the different stages of the disease.
Literatur
1.
Zurück zum Zitat Maloney WF, Robertson DM, Duboff SM (1977) Hereditary vitelliform macular degeneration: variable fundus findings within a single pedigree. Arch Ophthalmol 95:979–983PubMed Maloney WF, Robertson DM, Duboff SM (1977) Hereditary vitelliform macular degeneration: variable fundus findings within a single pedigree. Arch Ophthalmol 95:979–983PubMed
2.
Zurück zum Zitat Gass JDM (1997) Stereoscopic atlas of macular diseases, diagnosis and treatment. Mosby, St. Louis Gass JDM (1997) Stereoscopic atlas of macular diseases, diagnosis and treatment. Mosby, St. Louis
3.
Zurück zum Zitat Stone EM, Nichols BE, Streb LM, Kimura AE, Sheffield VC (1992) Genetic linkage of vitelliform macular degeneration (Best’s disease) to chromosome 11q13. Nat Genet 1:246–250CrossRefPubMed Stone EM, Nichols BE, Streb LM, Kimura AE, Sheffield VC (1992) Genetic linkage of vitelliform macular degeneration (Best’s disease) to chromosome 11q13. Nat Genet 1:246–250CrossRefPubMed
4.
Zurück zum Zitat Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, Sandgren O, Forsman K, Holmgren G, Andreasson S, Vujic M, Bergen AAB, McGarty-Dugan V, Figueroa D, Austin CP, Metzker ML, Caskey CT, Wadelius C (1998) Identification of the gene responsible for Best macular dystrophy. Nat Genet 19:241–247CrossRefPubMed Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, Sandgren O, Forsman K, Holmgren G, Andreasson S, Vujic M, Bergen AAB, McGarty-Dugan V, Figueroa D, Austin CP, Metzker ML, Caskey CT, Wadelius C (1998) Identification of the gene responsible for Best macular dystrophy. Nat Genet 19:241–247CrossRefPubMed
5.
Zurück zum Zitat Marquardt A, Stohr H, Passmore LA, Kramer F, Rivera A, Weber BH (1998) Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best disease). Hum Mol Genet 7:1517–1525CrossRefPubMed Marquardt A, Stohr H, Passmore LA, Kramer F, Rivera A, Weber BH (1998) Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best disease). Hum Mol Genet 7:1517–1525CrossRefPubMed
6.
Zurück zum Zitat Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K (2000) Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci USA 97:12758–12763CrossRefPubMed Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K (2000) Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci USA 97:12758–12763CrossRefPubMed
7.
Zurück zum Zitat Bakall B, McLaughlin P, Stanton JB, Zhang Y, Hartzell HC, Marmorstein LY, Marmorstein AD (2008) Bestrophin-2 is involved in the generation of intraocular pressure. Invest Ophthalmol Vis Sci 49:1563–1570CrossRefPubMed Bakall B, McLaughlin P, Stanton JB, Zhang Y, Hartzell HC, Marmorstein LY, Marmorstein AD (2008) Bestrophin-2 is involved in the generation of intraocular pressure. Invest Ophthalmol Vis Sci 49:1563–1570CrossRefPubMed
8.
Zurück zum Zitat Yu K, Qu Z, Cui Y, Hartzell HC (2007) Chloride channel activity of bestrophin mutants associated with mild or late-onset macular degeneration. Invest Ophthalmol Vis Sci 48:4694–4705CrossRefPubMed Yu K, Qu Z, Cui Y, Hartzell HC (2007) Chloride channel activity of bestrophin mutants associated with mild or late-onset macular degeneration. Invest Ophthalmol Vis Sci 48:4694–4705CrossRefPubMed
9.
Zurück zum Zitat Boon CJF, Klevering BJ, Leroy BP, Hoyng CB, Keunen JEE, den Hollander AI (2009) The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res 28:187–205CrossRefPubMed Boon CJF, Klevering BJ, Leroy BP, Hoyng CB, Keunen JEE, den Hollander AI (2009) The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res 28:187–205CrossRefPubMed
10.
Zurück zum Zitat Tsunenari T, Sun H, Williams J, Cahill H, Smallwood P, Yau KW, Nathans J (2003) Structure-function analysis of the bestrophin family of anion channels. J Biol Chem 278:41114–41125CrossRefPubMed Tsunenari T, Sun H, Williams J, Cahill H, Smallwood P, Yau KW, Nathans J (2003) Structure-function analysis of the bestrophin family of anion channels. J Biol Chem 278:41114–41125CrossRefPubMed
11.
Zurück zum Zitat Marmorstein AD, Kinnick TR (2007) Focus on molecules: Bestrophin (Best-1). Exp Eye Res 85:423–424CrossRefPubMed Marmorstein AD, Kinnick TR (2007) Focus on molecules: Bestrophin (Best-1). Exp Eye Res 85:423–424CrossRefPubMed
12.
Zurück zum Zitat Sun H, Tsunenari T, Yau KW, Nathans J (2002) The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci USA 99:4008–4013CrossRefPubMed Sun H, Tsunenari T, Yau KW, Nathans J (2002) The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci USA 99:4008–4013CrossRefPubMed
13.
Zurück zum Zitat Yu K, Cui Y, Hartzell HC (2006) The bestrophin mutation A243V, linked to adult-onset vitelliform macular dystrophy, impairs its chloride channel function. Invest Ophthalmol Vis Sci 47:4956–4961CrossRefPubMed Yu K, Cui Y, Hartzell HC (2006) The bestrophin mutation A243V, linked to adult-onset vitelliform macular dystrophy, impairs its chloride channel function. Invest Ophthalmol Vis Sci 47:4956–4961CrossRefPubMed
14.
Zurück zum Zitat Hartzell HC, Qu Z, Yu K, Xiao Q, Chien LT (2008) Molecular physiology of bestrophins: multifunctional membrane proteins linked to Best disease and other retinopathies. Physiol Rev 88:639–672CrossRefPubMed Hartzell HC, Qu Z, Yu K, Xiao Q, Chien LT (2008) Molecular physiology of bestrophins: multifunctional membrane proteins linked to Best disease and other retinopathies. Physiol Rev 88:639–672CrossRefPubMed
15.
Zurück zum Zitat Marmorstein AD, Cross HE, Peachey NS (2009) Functional roles of bestrophins in ocular epithelia. Prog Retin Eye Res 28:206–226CrossRefPubMed Marmorstein AD, Cross HE, Peachey NS (2009) Functional roles of bestrophins in ocular epithelia. Prog Retin Eye Res 28:206–226CrossRefPubMed
16.
Zurück zum Zitat Best F (1905) Über eine hereditäre Makulaaffektion. Z F Augenheilk 13:199–212 Best F (1905) Über eine hereditäre Makulaaffektion. Z F Augenheilk 13:199–212
17.
Zurück zum Zitat Deutman AF (1969) Electro-oculography in families with vitelliform dystrophy of the fovea. Detection of the carrier state. Arch Ophthalmol 81:305–316PubMed Deutman AF (1969) Electro-oculography in families with vitelliform dystrophy of the fovea. Detection of the carrier state. Arch Ophthalmol 81:305–316PubMed
18.
Zurück zum Zitat Cross HE, Bard L (1974) Electro-oculography in Best macular dystrophy. Am J Ophthalmol 77:46–50PubMed Cross HE, Bard L (1974) Electro-oculography in Best macular dystrophy. Am J Ophthalmol 77:46–50PubMed
19.
Zurück zum Zitat Glybina IV, Frank RN (2006) Localization of multifocal electroretinogram abnormalities to the lesion site: findings in a family with Best disease. Arch Ophthalmol 124:1593–1600CrossRefPubMed Glybina IV, Frank RN (2006) Localization of multifocal electroretinogram abnormalities to the lesion site: findings in a family with Best disease. Arch Ophthalmol 124:1593–1600CrossRefPubMed
20.
Zurück zum Zitat Boon CJF, Theelen T, Hoefsloot EH, van Schooneveld MJ, Keunen JEE, Cremers FPM, Klevering BJ, Hoyng CB (2009) Clinical and molecular genetic analysis of Best vitelliform macular dystrophy. Retina 29:835–847CrossRefPubMed Boon CJF, Theelen T, Hoefsloot EH, van Schooneveld MJ, Keunen JEE, Cremers FPM, Klevering BJ, Hoyng CB (2009) Clinical and molecular genetic analysis of Best vitelliform macular dystrophy. Retina 29:835–847CrossRefPubMed
21.
Zurück zum Zitat Renner AB, Tillack H, Kraus H, Kramer F, Mohr N, Weber BHF, Foerster MH, Kellner U (2005) Late onset is common in Best macular dystrophy associated with VMD2 gene mutations. Ophthalmology 112:586–592CrossRefPubMed Renner AB, Tillack H, Kraus H, Kramer F, Mohr N, Weber BHF, Foerster MH, Kellner U (2005) Late onset is common in Best macular dystrophy associated with VMD2 gene mutations. Ophthalmology 112:586–592CrossRefPubMed
22.
Zurück zum Zitat Wabbels B, Preising MN, Kretschmann U, Demmler A, Lorenz B (2006) Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol 244:1453–1466CrossRefPubMed Wabbels B, Preising MN, Kretschmann U, Demmler A, Lorenz B (2006) Genotype-phenotype correlation and longitudinal course in ten families with Best vitelliform macular dystrophy. Graefes Arch Clin Exp Ophthalmol 244:1453–1466CrossRefPubMed
23.
Zurück zum Zitat Boon CJ, Klevering BJ, den Hollander AI, Zonneveld MN, Theelen T, Cremers FPM, Hoyng CB (2007) Clinical and genetic heterogeneity in multifocal vitelliform dystrophy. Arch Ophthalmol 125:1100–1106CrossRefPubMed Boon CJ, Klevering BJ, den Hollander AI, Zonneveld MN, Theelen T, Cremers FPM, Hoyng CB (2007) Clinical and genetic heterogeneity in multifocal vitelliform dystrophy. Arch Ophthalmol 125:1100–1106CrossRefPubMed
24.
Zurück zum Zitat Mohler CW, Fine SL (1981) Long-term evaluation of patients with Best vitelliform dystrophy. Ophthalmology 88:688–692PubMed Mohler CW, Fine SL (1981) Long-term evaluation of patients with Best vitelliform dystrophy. Ophthalmology 88:688–692PubMed
25.
Zurück zum Zitat Boon CJ, Klevering JB, Keunen JE, Hoyng CB, Theelen T (2008) Fundus autofluorescence imaging of retinal dystrophies. Vis Res 48:2569–2577CrossRefPubMed Boon CJ, Klevering JB, Keunen JE, Hoyng CB, Theelen T (2008) Fundus autofluorescence imaging of retinal dystrophies. Vis Res 48:2569–2577CrossRefPubMed
26.
Zurück zum Zitat Querques G, Regenbogen M, Soubrane G, Souied EH (2009) High-resolution spectral domain optical coherence tomography findings in multifocal vitelliform macular dystrophy. Surv Ophthalmol 54:311–316CrossRefPubMed Querques G, Regenbogen M, Soubrane G, Souied EH (2009) High-resolution spectral domain optical coherence tomography findings in multifocal vitelliform macular dystrophy. Surv Ophthalmol 54:311–316CrossRefPubMed
27.
Zurück zum Zitat Noble KG, Scher BM, Carr RE (1978) Polymorphous presentations in vitelliform macular dystrophy: subretinal neovascularization and central choroidal atrophy. Br J Ophthalmol 62:561–570CrossRefPubMed Noble KG, Scher BM, Carr RE (1978) Polymorphous presentations in vitelliform macular dystrophy: subretinal neovascularization and central choroidal atrophy. Br J Ophthalmol 62:561–570CrossRefPubMed
28.
Zurück zum Zitat Frangieh GT, Green WR, Fine SL (1982) A histopathologic study of Best macular dystrophy. Arch Ophthalmol 100:1115–1121PubMed Frangieh GT, Green WR, Fine SL (1982) A histopathologic study of Best macular dystrophy. Arch Ophthalmol 100:1115–1121PubMed
29.
Zurück zum Zitat O’Gorman S, Flaherty WA, Fishman GA, Berson EL (1988) Histopathologic findings in Best vitelliform macular dystrophy. Arch Ophthalmol 106:1261–1268PubMed O’Gorman S, Flaherty WA, Fishman GA, Berson EL (1988) Histopathologic findings in Best vitelliform macular dystrophy. Arch Ophthalmol 106:1261–1268PubMed
30.
Zurück zum Zitat Blodi CF, Stone EM (1990) Best vitelliform dystrophy. Ophthalmic Paediatr Genet 11:49–59PubMed Blodi CF, Stone EM (1990) Best vitelliform dystrophy. Ophthalmic Paediatr Genet 11:49–59PubMed
31.
Zurück zum Zitat Fishman GA, Baca W, Alexander KR, Derlacki DJ, Glenn AM, Viana M (1993) Visual acuity in patients with Best vitelliform macular dystrophy. Ophthalmology 100:1665–1670PubMed Fishman GA, Baca W, Alexander KR, Derlacki DJ, Glenn AM, Viana M (1993) Visual acuity in patients with Best vitelliform macular dystrophy. Ophthalmology 100:1665–1670PubMed
32.
Zurück zum Zitat Chung MM, Oh KT, Streb LM, Kimura AE, Stone EM (2001) Visual outcome following subretinal hemorrhage in Best disease. Retina 21:575–580CrossRefPubMed Chung MM, Oh KT, Streb LM, Kimura AE, Stone EM (2001) Visual outcome following subretinal hemorrhage in Best disease. Retina 21:575–580CrossRefPubMed
33.
Zurück zum Zitat Andrade RE, Farah ME, Cardillo JA, Hofling-Lima AL, Uno F, Costa RA (2002) Optical coherence tomography in choroidal neovascular membrane associated with Best vitelliform dystrophy. Acta Ophthalmol Scand 80:216–218CrossRefPubMed Andrade RE, Farah ME, Cardillo JA, Hofling-Lima AL, Uno F, Costa RA (2002) Optical coherence tomography in choroidal neovascular membrane associated with Best vitelliform dystrophy. Acta Ophthalmol Scand 80:216–218CrossRefPubMed
34.
Zurück zum Zitat Andrade RE, Farah ME, Costa RA (2003) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Best disease. Am J Ophthalmol 136:1179–1181CrossRefPubMed Andrade RE, Farah ME, Costa RA (2003) Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Best disease. Am J Ophthalmol 136:1179–1181CrossRefPubMed
35.
Zurück zum Zitat Leu J, Schrage NF, Degenring RF (2007) Choroidal neovascularization secondary to Best disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 245:1723–1725CrossRefPubMed Leu J, Schrage NF, Degenring RF (2007) Choroidal neovascularization secondary to Best disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 245:1723–1725CrossRefPubMed
36.
Zurück zum Zitat Querques G, Bocco MC, Soubrane G, Souied EH (2008) Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy. Acta Ophthalmol 86:694–695CrossRefPubMed Querques G, Bocco MC, Soubrane G, Souied EH (2008) Intravitreal ranibizumab (Lucentis) for choroidal neovascularization associated with vitelliform macular dystrophy. Acta Ophthalmol 86:694–695CrossRefPubMed
37.
Zurück zum Zitat Bakall B, Marknell T, Ingvast S, Koisti MJ, Sandgren O, Li W, Bergen AAB, Andreasson S, Rosenberg T, Petrukhin K, Wadelius C (1999) The mutation spectrum of the bestrophin protein—functional implications. Hum Genet 104:383–389CrossRefPubMed Bakall B, Marknell T, Ingvast S, Koisti MJ, Sandgren O, Li W, Bergen AAB, Andreasson S, Rosenberg T, Petrukhin K, Wadelius C (1999) The mutation spectrum of the bestrophin protein—functional implications. Hum Genet 104:383–389CrossRefPubMed
38.
Zurück zum Zitat Kramer F, White K, Pauleikhoff D, Gehrig A, Passmore L, Rivera A, Rudolph G, Kellner U, Andrassi M, Lorenz B, Rohrschneider K, Blankenagel A, Jurklies B, Schilling H, Schutt F, Holz FG, Weber BH (2000) Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult-onset vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet 8:286–292CrossRefPubMed Kramer F, White K, Pauleikhoff D, Gehrig A, Passmore L, Rivera A, Rudolph G, Kellner U, Andrassi M, Lorenz B, Rohrschneider K, Blankenagel A, Jurklies B, Schilling H, Schutt F, Holz FG, Weber BH (2000) Mutations in the VMD2 gene are associated with juvenile-onset vitelliform macular dystrophy (Best disease) and adult-onset vitelliform macular dystrophy but not age-related macular degeneration. Eur J Hum Genet 8:286–292CrossRefPubMed
39.
Zurück zum Zitat Brown M, Marmor M, Vaegan ZE, Brigell M, Bach M, ISCEV (2006) ISCEV standard for clinical electro-oculography (EOG). Doc Ophthalmol 113:205–212CrossRefPubMed Brown M, Marmor M, Vaegan ZE, Brigell M, Bach M, ISCEV (2006) ISCEV standard for clinical electro-oculography (EOG). Doc Ophthalmol 113:205–212CrossRefPubMed
40.
Zurück zum Zitat Srinivasan VJ, Monson BK, Wojtkowski M, Bilonick RA, Gorczynska I, Chen R, Duker JS, Schuman JS, Fujimoto JG (2008) Characterization of outer retinal morphology with high-speed, ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci 49:1571–1579CrossRefPubMed Srinivasan VJ, Monson BK, Wojtkowski M, Bilonick RA, Gorczynska I, Chen R, Duker JS, Schuman JS, Fujimoto JG (2008) Characterization of outer retinal morphology with high-speed, ultrahigh-resolution optical coherence tomography. Invest Ophthalmol Vis Sci 49:1571–1579CrossRefPubMed
41.
Zurück zum Zitat Mullins RF, Kuehn MH, Faidley EA, Syed NA, Stone EM (2007) Differential macular and peripheral expression of bestrophin in human eyes and its implication for Best disease. Invest Ophthalmol Vis Sci 48:3372–3380CrossRefPubMed Mullins RF, Kuehn MH, Faidley EA, Syed NA, Stone EM (2007) Differential macular and peripheral expression of bestrophin in human eyes and its implication for Best disease. Invest Ophthalmol Vis Sci 48:3372–3380CrossRefPubMed
42.
Zurück zum Zitat Deguchi J, Yamamoto A, Yoshimori T, Sugasawa K, Moriyama Y, Futai M, Suzuki T, Kato K, Uyama M, Tashiro Y (1994) Acidification of phagosomes and degradation of rod outer segments in rat retinal pigment epithelium. Invest Ophthalmol Vis Sci 35:568–579PubMed Deguchi J, Yamamoto A, Yoshimori T, Sugasawa K, Moriyama Y, Futai M, Suzuki T, Kato K, Uyama M, Tashiro Y (1994) Acidification of phagosomes and degradation of rod outer segments in rat retinal pigment epithelium. Invest Ophthalmol Vis Sci 35:568–579PubMed
43.
Zurück zum Zitat Jentsch TJ (2007) Chloride and the endosomal-lysosomal pathway: emerging roles of CLC chloride transporters. J Physiol 578:633–640CrossRefPubMed Jentsch TJ (2007) Chloride and the endosomal-lysosomal pathway: emerging roles of CLC chloride transporters. J Physiol 578:633–640CrossRefPubMed
44.
Zurück zum Zitat Karl MO, Kroeger W, Wimmers S, Milenkovic VM, Valtink M, Engelmann K, Strauss O (2008) Endogenous Gas6 and Ca2+-channel activation modulate phagocytosis by retinal pigment epithelium. Cell Signal 20:1159–1168CrossRefPubMed Karl MO, Kroeger W, Wimmers S, Milenkovic VM, Valtink M, Engelmann K, Strauss O (2008) Endogenous Gas6 and Ca2+-channel activation modulate phagocytosis by retinal pigment epithelium. Cell Signal 20:1159–1168CrossRefPubMed
45.
Zurück zum Zitat Rosenthal R, Heimann H, Agostini H, Martin G, Hansen LL, Strauss O (2007) Ca2+ channels in retinal pigment epithelial cells regulate vascular endothelial growth factor secretion rates in health and disease. Mol Vis 13:443–456PubMed Rosenthal R, Heimann H, Agostini H, Martin G, Hansen LL, Strauss O (2007) Ca2+ channels in retinal pigment epithelial cells regulate vascular endothelial growth factor secretion rates in health and disease. Mol Vis 13:443–456PubMed
46.
Zurück zum Zitat Weingeist T, Kobrin J, Watzke R (1982) Histopathology of Best macular dystrophy. Arch Ophthalmol 100:1108–1114PubMed Weingeist T, Kobrin J, Watzke R (1982) Histopathology of Best macular dystrophy. Arch Ophthalmol 100:1108–1114PubMed
47.
Zurück zum Zitat Mullins RF, Oh KT, Heffron E, Hageman G, Stone EM (2005) Late development of vitelliform lesions and flecks in a patient with Best disease. Arch Ophthalmol 123:1588–1594CrossRefPubMed Mullins RF, Oh KT, Heffron E, Hageman G, Stone EM (2005) Late development of vitelliform lesions and flecks in a patient with Best disease. Arch Ophthalmol 123:1588–1594CrossRefPubMed
48.
Zurück zum Zitat Bakall B, Radu RA, Stanton JB, Burke JM, McKay BS, Wadelius C, Mullins RF, Stone EM, Travis GH, Marmorstein AD (2007) Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res 85:34–43CrossRefPubMed Bakall B, Radu RA, Stanton JB, Burke JM, McKay BS, Wadelius C, Mullins RF, Stone EM, Travis GH, Marmorstein AD (2007) Enhanced accumulation of A2E in individuals homozygous or heterozygous for mutations in BEST1 (VMD2). Exp Eye Res 85:34–43CrossRefPubMed
49.
Zurück zum Zitat Pianta MJ, Aleman TS, Cideciyan AV, Sunness JS, Li Y, Campochiaro BA, Campochiaro PA, Zack DJ, Stone EM, Jacobson SG (2003) In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res 76:203–211CrossRefPubMed Pianta MJ, Aleman TS, Cideciyan AV, Sunness JS, Li Y, Campochiaro BA, Campochiaro PA, Zack DJ, Stone EM, Jacobson SG (2003) In vivo micropathology of Best macular dystrophy with optical coherence tomography. Exp Eye Res 76:203–211CrossRefPubMed
50.
Zurück zum Zitat Men G, Batioglu F, Ozkan SS, Huban A, Ozdamar Y, Aslan O (2004) Best vitelliform macular dystrophy with pseudohypopyon: an optical coherence tomography study. Am J Ophthalmol 137:963–965CrossRefPubMed Men G, Batioglu F, Ozkan SS, Huban A, Ozdamar Y, Aslan O (2004) Best vitelliform macular dystrophy with pseudohypopyon: an optical coherence tomography study. Am J Ophthalmol 137:963–965CrossRefPubMed
51.
Zurück zum Zitat Vedantham V, Ramasamy K (2005) Optical coherence tomography in Best disease: an observational case report. Am J Ophthalmol 139:351–353CrossRefPubMed Vedantham V, Ramasamy K (2005) Optical coherence tomography in Best disease: an observational case report. Am J Ophthalmol 139:351–353CrossRefPubMed
52.
Zurück zum Zitat Spaide RF, Noble K, Morgan A, Freund KB (2006) Vitelliform macular dystrophy. Ophthalmology 113:1392–1400CrossRefPubMed Spaide RF, Noble K, Morgan A, Freund KB (2006) Vitelliform macular dystrophy. Ophthalmology 113:1392–1400CrossRefPubMed
53.
Zurück zum Zitat Spaide RF (2008) Autofluorescence from the outer retina and subretinal space. Hypothesis and review. Retina 28:5–35CrossRefPubMed Spaide RF (2008) Autofluorescence from the outer retina and subretinal space. Hypothesis and review. Retina 28:5–35CrossRefPubMed
54.
Zurück zum Zitat Querques G, Regenbogen M, Quijano C, Delphin N, Soubrane G, Souied EH (2008) High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol 146:501–507CrossRefPubMed Querques G, Regenbogen M, Quijano C, Delphin N, Soubrane G, Souied EH (2008) High-definition optical coherence tomography features in vitelliform macular dystrophy. Am J Ophthalmol 146:501–507CrossRefPubMed
55.
Zurück zum Zitat Zawadzki RJ, Jones SM, Olivier SS, Zhao M, Bower BA, Izatt JA, Choi S, Laut S, Werner JS (2005) Adaptive-optics optical coherence tomography for high-resolution and high-speed 3D retinal in vivo imaging. Opt Express 13:8532–8546CrossRefPubMed Zawadzki RJ, Jones SM, Olivier SS, Zhao M, Bower BA, Izatt JA, Choi S, Laut S, Werner JS (2005) Adaptive-optics optical coherence tomography for high-resolution and high-speed 3D retinal in vivo imaging. Opt Express 13:8532–8546CrossRefPubMed
56.
Zurück zum Zitat Verhoeff FH (1903) A hitherto undescribed membrane of the eye and its significance. Boston Med Surg J 149:456 Verhoeff FH (1903) A hitherto undescribed membrane of the eye and its significance. Boston Med Surg J 149:456
57.
Zurück zum Zitat Maia-Lopes S, Silva ED, Reis A, Silva MF, Mateus C, Castelo-Branco M (2008) Retinal function in Best macular dystrophy: relationship between electrophysiological, pychophysical, and structural measures of damage. Invest Ophthalmol Vis Sci 49:5553–5560CrossRefPubMed Maia-Lopes S, Silva ED, Reis A, Silva MF, Mateus C, Castelo-Branco M (2008) Retinal function in Best macular dystrophy: relationship between electrophysiological, pychophysical, and structural measures of damage. Invest Ophthalmol Vis Sci 49:5553–5560CrossRefPubMed
Metadaten
Titel
Multimodal fundus imaging in Best vitelliform macular dystrophy
verfasst von
Daniela C. Ferrara
Rogério A. Costa
Stephen Tsang
Daniela Calucci
Rodrigo Jorge
K. Bailey Freund
Publikationsdatum
01.10.2010
Verlag
Springer-Verlag
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 10/2010
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-010-1381-2

Weitere Artikel der Ausgabe 10/2010

Graefe's Archive for Clinical and Experimental Ophthalmology 10/2010 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.